A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)

• Published in: Therapeutics and clinical risk management Vol. 2008; no. Issue 1; pp. 235 - 244
• Main Authors: Lala M Dunbar, Derek M Tang, Robert M Manausa
• Format: Journal Article
• Language: English
• Published: Dove Medical Press 01.03.2008
• ISSN: 1176-6336; 1178-203X

Lala M Dunbar1, Derek M Tang2, Robert M Manausa11Louisiana State University Health Sciences Center, New Orleans, USA; 2Tulane University School of Medicine, USAAbstract: Telavancin is a novel antibiotic being investigated for the treatment of serious infections caused by Gram-positive bacteria, including complicated skin and skin structure infections (cSSSI) and pneumonia. This once-daily intravenous lipoglycopeptide exerts rapid bactericidal activity via a dual mechanism of action. It is intended for use to combat infections caused by Staphylococcus aureus and other Gram-positive bacteria, including methicillin-resistant and vancomycin-intermediate strains of S. aureus (MRSA and VISA, respectively). Vancomycin is the current gold standard in treating serious infections caused by Gram-positive bacteria, especially MRSA. In recent clinical trials, telavancin has shown excellent efficacy in phase II and III multinational, randomized, double-blinded studies of cSSSI. In the phase II FAST 2 study, which compared telavancin 10 mg/kg intravenously q 24 h vs standard therapy (an antistaphylococcal penicillin at 2 g IV q 6 h or vancomycin 1 gm IV q 12 h), the clinical success rate in the telavancin-treated group was 96% vs 94% in the standard therapy group. In two identical phase III trials comparing telavancin versus vancomycin at the doses of the FAST 2 study for cSSSI, the clinical cure rates were 88.3% and 87.1%, respectively. Two additional phase III clinical trials investigating telavancin for use in hospital-acquired pneumonia, caused by Gram-positive bacteria are currently ongoing. Telavancin is currently under regulatory review in both the United States and Europe for the indication of treatment of cSSSI.Keywords: telavancin, vancomycin, MRSA